Replying to @AndrewDigby3
Relax Capt 😊
We got the major news (early) that we wanted.
PK & PD is seemingly working as expected. Therefore Exatecan will 90+% chance do the same.
Don’t worry about the SP or the raise. Neither matter too much vs the bigger picture. Enjoy the weekend mate
1
10
218
I think this has largely been missed by investors so worth highlighting because if you understand the below illustrations, you’ll realise that the 6103 trial has another hugely significant differential from the 6k trial (which feels like its been running since 1987) 😉
1/3 #avct
Mixed thoughts on #avct RNS. Mainly positive. I hoped for closer to 70p however either way it’s not a huge raise.
I must admit I did like this section which pretty much confirms the 6k trials are deal worthy
We’ve asked for a while, how do you price it? Maybe H2 we get answers
#avct 6103 likely gets another one over ADC rivals
Extended shelf life @ higher temps (fridge not freezer)
Easier reconstitution at clinic (add diluent before IV administration)
Standard refrigerated logistics, lower risk of excursions, & reduced distribution costs/complexity
Still buzzing about the removal of Max Dosing Limit for Faridox.
CC is 🥇
Does her master plan include for increasing patient numbers in P1b to drive up odds of achieving breakthrough therapy status for 6k pre-P2?
This being the milestone for a huge uplift in deal value…..#avct
6103 IND APPROVED 🫶🏻
#AVCT
Avacta is pleased to announce U.S. FDA clearance of the IND application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan. avacta.com/avacta-announces-… #AVCT







